Related references
Note: Only part of the references are listed.The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels A Retrospective Multicenter Cohort Study
Mohammad Hosein Aziz et al.
ANNALS OF SURGERY (2019)
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma
Kazuki Takada et al.
PLOS ONE (2019)
Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations
Hongwei Li et al.
GENES AND IMMUNITY (2019)
Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer
Kaushal Parikh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
A novel systemic immune-inflammation index predicts survival and quality of life of patients after curative resection for esophageal squamous cell carcinoma
Lu Wang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils
Camilla Engblom et al.
SCIENCE (2017)
Systemic immune-inflammation index for predicting prognosis of colorectal cancer
Jian-Hui Chen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer
Hideya Takeuchi et al.
PLOS ONE (2017)
High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy
Keisuke Shigeta et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
Cristian Lolli et al.
FRONTIERS IN PHARMACOLOGY (2016)
Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis
Yiting Geng et al.
SCIENTIFIC REPORTS (2016)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer
Xuan Hong et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients
Guannan Wu et al.
THORACIC CANCER (2015)
Smoking, inflammation and small cell lung cancer: recent developments
Gerhard Hamilton et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2015)
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Bo Hu et al.
CLINICAL CANCER RESEARCH (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival
Patricia Gonzalez-Arriaga et al.
BMC CANCER (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Association between Polymorphisms in the Promoter Regions of Matrix Metalloproteinases (MMPs) and Risk of Cancer Metastasis: A Meta-Analysis
Dan Liu et al.
PLOS ONE (2012)
Origins of tumor-associated macrophages and neutrophils
Virna Cortez-Retamozo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
EGFR Mutations and Lung Cancer
Gilda da Cunha Santos et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
Samantha Solito et al.
BLOOD (2011)
Tumor-Associated Neutrophils: New Targets for Cancer Therapy
Alyssa D. Gregory et al.
CANCER RESEARCH (2011)
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Chenguang Li et al.
PLOS ONE (2011)
Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Martin L. Sos et al.
CANCER RESEARCH (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status
Takamitsu Onitsuka et al.
LUNG CANCER (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
IFNα activates dormant haematopoietic stem cells in vivo
Marieke A. G. Essers et al.
NATURE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The I kappa B kinase - a bridge between inflammation and cancer
Michael Karin
CELL RESEARCH (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Molecular origins of cancer: Lung cancer
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy
A Sica et al.
EUROPEAN JOURNAL OF CANCER (2006)
Share Paper
